Business Wire

Aera Technology Releases New Capabilities to Accelerate Decision Intelligence Adoption

Share

Gartner Supply Chain Symposium/Xpo™ 2022 Aera Technology today announced from the Gartner® Supply Chain Symposium/Xpo™ 2022, the release of new AI/MLOps and developer capabilities for its Aera Decision Cloud™ platform. To speed and scale decision automation, these enhancements add to the platform’s data science engine and provide advanced features for understanding the relationships and effectiveness of decisions. The innovations also strengthen Aera Decision Cloud’s capabilities for supply chain decision flows.

Aera Decision Cloud is designed to accelerate the adoption of Decision Intelligence — the digitization, augmentation, and automation of decision making. It enables companies to make and execute decisions in real-time to optimize business, financial, and operational performance.

According to Gartner, “by 2025, 95% of decisions that currently use data will be at least partially automated.”* Implementing and scaling automated decision-making across one or multiple business functions is difficult and time-consuming without a purpose-built platform. Aera Decision Cloud was designed from the start to empower users with the advanced technologies and tools, in one platform, to aggregate and integrate data from internal and external systems and sources and build and deploy decision-making models that generate informed, automated recommendations for any business scenario.

Today’s product release provides new features for business users that advance and scale Aera Cognitive Skills™ — the platform’s pre-built set of comprehensive decision-making capabilities for demand forecasting, planning, inventory, logistics, procurement, finance, revenue, and more. The release also delivers enhancements for data engineers, data scientists, and developers that optimize their experience in Aera Developer™, the platform’s integrated development environment (IDE) for creating and deploying Skills, or modifying any deployed Aera Cognitive Skills.

Product release highlights:

  • Enhancements to Aera Cortex™, the data science engine inside the Aera Cognitive Operating System™, to improve the user experience, including:
    • New Aera Notebook: Jupyter Notebook open interface provides the ideal environment to easily integrate data science projects and other custom code using Python and R, into Decision Intelligence flows, right from the Aera Decision Cloud platform.
    • New AutoML: Machine learning options enable development of ML decision models — without requiring expertise in model creation, tuning, and deployment.
    • New Model Performance and Versioning: New enhancements automate monitoring, deployment, and versioning of machine learning models to make it much easier to operationalize ML models and scale across the entire enterprise.
  • Advanced intelligence capabilities to provide a deeper understanding of relationships and effectiveness of decisions, including:
    • New Graph Explorer: Advanced graph capabilities to enable data relationships to be used effectively in the decision-making process.
    • New Confidence Score: Confidence score framework, which learns from past, similar recommendations and outcomes, helps determine the decisions that can be automated.
    • New Action Item Node: Addition of a node within the Aera Developer environment to simplify decision management through the ability to more easily create, update, close, and access recommendations.

“Through Aera Decision Cloud, we are re-inventing decision making and accelerating adoption of Decision Intelligence,” said Shariq Mansoor, Founder and Chief Technology Officer, Aera Technology. "Today’s comprehensive release for both business end user and data science teams underscores how we are continually advancing and evolving our platform to enable digital decisions at scale in this increasingly complex business environment.”

To see a demo of Aera Decision Cloud and the new features, visit the Aera team at Booth #325, Gartner Supply Chain Symposium/Xpo™ 2022.

About the Gartner Supply Chain Symposium/Xpo™

Gartner Supply Chain Symposium/Xpo delivers the must-have insights, strategies and frameworks for CSCOs and supply chain leaders to drive impact within their organizations. Supply chain leaders will gather to gain a strategic view of the trends disrupting their business and the insights and frameworks they can use to prepare for disruption, enable digital transformation and build sustainability as a competitive advantage.

*Gartner, Predicts 2022: Data and Analytics Strategies Build Trust and Accelerate Decision Making,” Jorgen Heizenberg, Lydia Clougherty Jones, Ted Friedman, Andrew White, Saul Judah, Gareth Herschel, Rita Sallam, Ehtisham Zaidi, Svetlana Sicular, December 2021. https://www.gartner.com/document/4008991

GARTNER and SUPPLY CHAIN SYMPOSIUM/XPO™ are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

About Aera Technology

Aera Technology is the Decision Intelligence company that makes business agility happen. The company’s innovative cloud platform integrates with existing systems to make and execute business decisions in real time. In the era of digital acceleration, Aera helps enterprises around the world transform how they respond to the ever-changing environment. For more information, visit www.aeratechnology.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Zoe Kine
Zoe.kine@aeratechnology.com
Ph: 415-497-5285

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye